Literature DB >> 13360869

Permanent bilateral blindness following the use of hexamethonium chloride.

G M BRUCE.   

Abstract

Entities:  

Keywords:  BLINDNESS/etiology and pathogenesis; HEXAMETHONIUM COMPOUNDS/injurious effects

Mesh:

Substances:

Year:  1955        PMID: 13360869      PMCID: PMC1312713     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


× No keyword cloud information.
  9 in total

1.  Evaluation of an androgen, methylandrostenediol, in the treatment of diabetic retinopathy.

Authors:  K J GURLING
Journal:  Br J Ophthalmol       Date:  1955-03       Impact factor: 4.638

2.  Outpatient treatment of hypertension with hexamethonium and hydralazine; a preliminary report.

Authors:  W P GALEN; J E DUKE
Journal:  South Med J       Date:  1954-09       Impact factor: 0.954

3.  The methonium.

Authors:  W D M PATON; E ZAIMIS
Journal:  Pharmacol Rev       Date:  1952-09       Impact factor: 25.468

4.  [Haemodynamics of methonium hypotension during anesthesia].

Authors:  R SHACKMAN; I G GRABER; D G MELROSE; J SMITH
Journal:  Anaesthesia       Date:  1952-10       Impact factor: 6.955

5.  Acute psychosis as a complication of hydralazine therapy in essential hypertension.

Authors:  M MOSER; J SYNER; S MALITZ; T W MATTINGLY
Journal:  J Am Med Assoc       Date:  1953-08-01

6.  Unilateral amaurosis with partial recovery after using hexamethonium iodide.

Authors:  A J B GOLDSMITH; A J H HEWER
Journal:  Br Med J       Date:  1952-10-04

7.  Hexamethonium and glaucoma.

Authors:  A J CAMERON; R A BURN
Journal:  Br J Ophthalmol       Date:  1952-09       Impact factor: 4.638

8.  [Effect of narcosis, of curare, and of ganglioplegics on intraocular tension].

Authors:  A COUADAU; L CAMPAN
Journal:  Arch Ophtalmol Rev Gen Ophtalmol       Date:  1952

9.  Results with oral hexamethonium alone and in combination with 1-hydrazinophthalazine (apresoline) in the therapy of hypertension.

Authors:  J H MOYER; B H SNYDER; I JOHNSON; L C MILLS; S I MILLER
Journal:  Am J Med Sci       Date:  1953-04       Impact factor: 2.378

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.